InC 01
Alternative Names: InC-01Latest Information Update: 16 Dec 2022
Price :
$50 *
At a glance
- Originator InCephalo Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain cancer
Most Recent Events
- 16 Dec 2022 Preclinical trials in Brain cancer in Switzerland (Parenteral) before December 2022 (InCephalo Therapeutics website, December 2022)
- 16 Dec 2022 InC 01 receives Orphan Drug status for Brain cancer in European Union before December 2022 (InCephalo Therapeutics website, December 2022)